Basel, Switzerland

Hans De Waard

This inventor holds 1 USPTO granted patent and 4 published patent applications and 1 EPO patent. Top assignee: Novartis Ag. Active years: 2023.

USPTO Granted Patents = 1 

% Patents Active = 100.0

 

Average Co-Inventor Count = 5.0

ph-index = 1


Company Filing History:


Years Active: 2023

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Hans De Waard

Introduction

Hans De Waard is a notable inventor based in Basel, Switzerland. He has made significant contributions to the field of pharmaceutical technology. His work primarily focuses on methods for preparing granules, which are essential in the formulation of various medications.

Latest Patents

Hans De Waard holds a patent for a "Method for preparing granules." This innovative method involves preparing a slurry containing solid active pharmaceutical ingredient (API) powder particles dispersed in a liquid. The slurry is then fed to a granulator, where it is mixed with a dry base powder to produce a slurry/base powder mixture. This mixture is subsequently dried to obtain granules that contain the solid API particles and the base powder. This patent showcases his expertise in enhancing pharmaceutical formulations.

Career Highlights

Hans De Waard is currently employed at Novartis AG, a leading global healthcare company. His role at Novartis allows him to apply his innovative ideas in a practical setting, contributing to the development of new pharmaceutical products. His work has been instrumental in improving the efficiency and effectiveness of drug formulations.

Collaborations

Throughout his career, Hans has collaborated with several talented individuals, including Julien Taillemite and Adrian Schmidt. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Hans De Waard's contributions to the field of pharmaceutical technology are noteworthy. His innovative methods for preparing granules have the potential to significantly impact the industry. His work at Novartis AG and collaborations with other professionals further highlight his commitment to advancing pharmaceutical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…